MENU
JUN 2, 2021 Opens: 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Immuno-Oncology 2021

LabRoots is pleased to announce the inauguration of the Immuno-Oncology Virtual Event taking place on June 2, 2021. Immuno-Oncology is considered by some to be one of the most promising areas of research in the world of anti-cancer therapeutics. Learn from our experts how immunotherapies can work alone, together, or in combination with other treatments to fight cancer.

This year's event includes the following tracks and topics:

New Advancements in Immuno-Oncology

  • Cell Therapy Innovation
  • Checkpoint Inhibitors
  • Innate Immunity Considerations
  • Microbiome and Cancer
  • New Adaptive Immunity Considerations

Emerging Targets for Immuno-Oncology Therapy

  • Overcoming Obstacles in the Immunosuppressive Tumor Micro-environment
  • Molecular and Epigenetic Modulation
  • Cancer Immunotherapeutics and COVID-19
  • Novel Cell Therapy Targets and Engineering Strategies

Advancing Cancer Immunotherapies to the Clinic

  • Translational
  • Clinical

Recent breakthroughs in immuno-oncology research translate into a paradigm shift with regards to attacking advancing cancer. The benefits of immuno-oncology have resulted in long-lasting tumor regression where surgery, radiotherapy, chemotherapy, and targeted therapy proved less effective.

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing.  This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.

Like the 2020 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.



Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2021 Immuno-Oncology Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.

Use #LRimmuno to follow the conversation!


Speakers

Show Resources
You May Also Like
JUN 08, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 08, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
The global pandemic has not only changed our plans for how we live and work, but also accelerated the need for innovation to protect human health. Join us for an Innovation Summit to hear fi...
JUN 17, 2021 3:00 PM BST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 17, 2021 3:00 PM BST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Each step in a diagnostic test's journey-from raw material extraction to patient administration-can influence outcomes....
NOV 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Twelveyears ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event will again bring together clinician...
NOV 09, 2022 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 09, 2022 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Thirteen years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2022 Clinical Diagnostics and Research Virtual Event will again bring together clinic...
JUN 09, 2021 6:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 09, 2021 6:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Bioprocess technology implementation is hard. Get ahead by getting it right. How do you know if you’re making the right decisions about bioproduction technologies? There is no universa...
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 7 th Ann...
Agenda
Scheduled
  • Dynamic live cell imaging of adherent and immune cells using CellASIC® ONIX2 microfluidic platform
    JUN 02, 2021 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Dynamic live cell imaging of adherent and immune cells using CellASIC® ONIX2 microfluidic platform
    Jun Park, PhD
    Senior Scientist, MilliporeSigma
    Sponsored By: MilliporeSigma
  • Industry Response to the Expanding Need in Immuno-Oncology for Validated Antibodies
    JUN 02, 2021 7:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Industry Response to the Expanding Need in Immuno-Oncology for Validated Antibodies
    Brian McWilliams, PhD
    IP/WB Manager at Fortis Life Sciences
    Sponsored By: Bethyl Laboratories, Inc.
  • JUN 02, 2021 7:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    xMAP® INTELLIFLEX and Immunoassay Innovations: Tools to advance immuno-oncology research
    Wilco de Jager, PhD, Sigrun Badrnya
    Sponsored By: LUMINEX
    Continuing Education: Florida CE | P.A.C.E. CE
    Wilco de Jager, PhD
    Sr. Field Applications Scientist, Luminex
    Sigrun Badrnya
    Product Development Manager, Thermo Fisher Scientific
  • Making sense out of multiplex
    JUN 02, 2021 9:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Making sense out of multiplex
    Dave Mason, PhD
    Technical Sales Specialist, Visiopharm
    Sponsored By: Visiopharm®
  • Keynote Presentation: New Checkpoints and Biomarkers
    JUN 02, 2021 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: New Checkpoints and Biomarkers
    Gordon Freeman, PhD
    Professor of Medicine, Harvard Medical School
    Continuing Education: Florida CE | P.A.C.E. CE
  • Keynote Presentation: Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance
    JUN 02, 2021 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance
    Michael A. Curran, PhD
    Associate Professor of Immunology, MD Anderson Cancer Center, The University of Texas
The following webinars will be readily on-demand when the event starts
  • Characterizing CAR T cell Responses to Low Density Antigens
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Characterizing CAR T cell Responses to Low Density Antigens
    Kole DeGolier, B.S.
    PhD Candidate - Fry Lab Department of Immunology University of Colorado
    Continuing Education: Florida CE | P.A.C.E. CE
  • Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma
    Peter Sullivan, PhD
    Postdoctoral Fellow, Laboratory of Dr. Rimas Orentas, Seattle Children's Research Institute
  • EZH2 as an Actionable Therapeutic Target to Enhance Anti-Tumor Immune Response In Prostate Cancer
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    EZH2 as an Actionable Therapeutic Target to Enhance Anti-Tumor Immune Response In Prostate Cancer
    Leigh Ellis, Ph.D.
    Acting Associate Professor of Medicine, Cedars-Sinai Medical Center
  • Fueling Antitumor Immunity Using Oncolytic Viruses Encoding Metabolic Modulators
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Fueling Antitumor Immunity Using Oncolytic Viruses Encoding Metabolic Modulators
    Dayana Rivadeneira, PhD
    Research Assistant Professor, Department of Immunology University of Pittsburgh
    Continuing Education: Florida CE | P.A.C.E. CE
  • IDO in Melanoma..... Deserves Further Evaluation
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    IDO in Melanoma..... Deserves Further Evaluation
    Yousef Zakharia, MD
    Associate Professor of Medicine, University of Iowa
  • Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma
    Adam Burrack, M.S., Ph.D.
    Researcher, University of Minnesota, Center for Immunology
  • Th17-Inducing Vaccines for the Treatment of Ovarian Cancer
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Th17-Inducing Vaccines for the Treatment of Ovarian Cancer
    Keith Knutson, PhD
    Professor of Immunology, Mayo Clinic
    Continuing Education: Florida CE | P.A.C.E. CE
  • Using genetically engineered preclinical models to study T cell therapy against solid tumors
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Using genetically engineered preclinical models to study T cell therapy against solid tumors
    Leah Schmidt, PhD
    Postdoctoral Fellow, Fred Hutchinson Cancer Research Center
  • Emerging Targets for Immuno-Oncology Therapy
  • Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma
    Adam Burrack, M.S., Ph.D.
    Researcher, University of Minnesota, Center for Immunology
  • Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma
    Peter Sullivan, PhD
    Postdoctoral Fellow, Laboratory of Dr. Rimas Orentas, Seattle Children's Research Institute
  • EZH2 as an Actionable Therapeutic Target to Enhance Anti-Tumor Immune Response In Prostate Cancer
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    EZH2 as an Actionable Therapeutic Target to Enhance Anti-Tumor Immune Response In Prostate Cancer
    Leigh Ellis, Ph.D.
    Acting Associate Professor of Medicine, Cedars-Sinai Medical Center
  • Fueling Antitumor Immunity Using Oncolytic Viruses Encoding Metabolic Modulators
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Fueling Antitumor Immunity Using Oncolytic Viruses Encoding Metabolic Modulators
    Dayana Rivadeneira, PhD
    Research Assistant Professor, Department of Immunology University of Pittsburgh
    Continuing Education: Florida CE | P.A.C.E. CE
  • Keynote Presentation: Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance
    JUN 02, 2021 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance
    Michael A. Curran, PhD
    Associate Professor of Immunology, MD Anderson Cancer Center, The University of Texas
  • New Advancements in Immuno-Oncology
  • Using genetically engineered preclinical models to study T cell therapy against solid tumors
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Using genetically engineered preclinical models to study T cell therapy against solid tumors
    Leah Schmidt, PhD
    Postdoctoral Fellow, Fred Hutchinson Cancer Research Center
  • Th17-Inducing Vaccines for the Treatment of Ovarian Cancer
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Th17-Inducing Vaccines for the Treatment of Ovarian Cancer
    Keith Knutson, PhD
    Professor of Immunology, Mayo Clinic
    Continuing Education: Florida CE | P.A.C.E. CE
  • Characterizing CAR T cell Responses to Low Density Antigens
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Characterizing CAR T cell Responses to Low Density Antigens
    Kole DeGolier, B.S.
    PhD Candidate - Fry Lab Department of Immunology University of Colorado
    Continuing Education: Florida CE | P.A.C.E. CE
  • Keynote Presentation: New Checkpoints and Biomarkers
    JUN 02, 2021 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: New Checkpoints and Biomarkers
    Gordon Freeman, PhD
    Professor of Medicine, Harvard Medical School
    Continuing Education: Florida CE | P.A.C.E. CE
  • Advancing Cancer Immunotherapies to the Clinic
  • IDO in Melanoma..... Deserves Further Evaluation
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    IDO in Melanoma..... Deserves Further Evaluation
    Yousef Zakharia, MD
    Associate Professor of Medicine, University of Iowa
Speakers

  • Michael A. Curran, PhD
    Associate Professor of Immunology, MD Anderson Cancer Center, The University of Texas
    Biography

      Dr. Curran received a Ph.D. in Immunology from Stanford University where he was awarded the McDevitt prize for the best graduate thesis in his year. Dr. Curran was the first recipient of the prestigious American Cancer Society Levy Fellowship to fund his post-doctoral studies in the lab of Dr. James P. Allison. While pursuing his postdoctoral studies at Memorial Sloan-Kettering Cancer Center, Dr. Curran published several influential manuscripts describing how T cell co-stimulatory pathways could be modulated in tandem to mediate immunologic rejection of melanomas in mice. Dr. Curran was the first to describe how combination blockade of the T cell co-inhibitory receptors CTLA-4 and PD-1 promoted the rejection of a majority of murine melanomas – a combination that remains the most effective FDA-approved immunotherapy. At the MD Anderson Cancer Center, Dr. Curran is an Associate Professor of Immunology and his Lab seeks to discover the underlying mechanisms of immune resistance in the “coldest” tumors, pancreatic and prostate adenocarcinoma and glioblastoma, so that rational therapeutic interventions can be developed to restore T cell infiltration and sensitivity to T cell checkpoint blockade.  This research focuses on normalization of tumor oxygen metabolism to increase T cell metabolic fitness, and on pro-inflammatory activation of tumor myeloid stroma.

    • Sigrun Badrnya
      Product Development Manager, Thermo Fisher Scientific
      Biography

        Sigrun Badrnya is Manager in Product Development at the Thermo Fisher Scientific Center of Excellence for Immunoassays in Vienna, Austria. Sigrun received her PhD in vascular biology from the Medical University of Vienna in Austria. She continued as postdoctoral researcher at the Karolinska Institute in Stockholm, Sweden and within an industry-academia joint project for Randox Laboratories UK, where she focused on the development of multiplex protein biomarker assays. In her current role she is supervising an R&D team to develop immunoassays across diverse platforms including Invitrogen ELISA, ProcartaPlex and ProQuantum.

      • Adam Burrack, M.S., Ph.D.
        Researcher, University of Minnesota, Center for Immunology
        Biography

          Dr. Burrack obtained B.S. in Biology at the University of Wisconsin and a M.S. in Physiology at the University of Wisconsin-La Crosse. He went on to complete his PhD in Immunology at the University of Colorado – Anschutz Medical Campus. Family history of both type 1 diabetes and pancreatic cancer have greatly influenced Dr. Burrack's scientific interests and research experiences. During graduate school, Dr. Burrack studied autoimmune diabetes recurrence and transplant recognition in a mouse model of type 1 diabetes in the laboratory of Ronald Gill. He then pursued post-doctoral at the University of Minnesota where he defined antigens that are recognized by alloreactive T cells direct transplant recognition. He also investigated how pancreatic beta cells respond to inflammation in the context of diabetes. With this background and specific interest in pancreatic diseases, he next joined the laboratory of Dr. Ingunn Stromnes at the University of Minnesota in the Center for Immunology. Over the past 3 years, he has developed novel mouse models of pancreatic cancer to interrogate the fate and functionality of tumor-specific T cells as well as mechanisms of immunotherapy resistance in the highly lethal disease, pancreatic cancer. This work has led to two first author publications in Cell Reports and Journal of Immunology. With these new models in hand, he is identifying novel strategies to enhance anti-tumor T cells in vivo to support pancreatic cancer eradication to inform clinical translation for pancreatic cancer patient treatment.

        • Wilco de Jager, PhD
          Sr. Field Applications Scientist, Luminex
          Biography

            Wilco de Jager has a background in pediatric immunology and obtained his PhD at Utrecht University, in the Netherlands in 2008. During an 18 year academic career he built a biomarker laboratory using xMAP® Technology as the core technology. He joined Luminex in 2018 as a Senior Field Application Scientist with a particular interest in custom assay design for both academia and industry.

          • Kole DeGolier, B.S.
            PhD Candidate - Fry Lab Department of Immunology University of Colorado
            Biography

              Mr. DeGolier obtained his B.S. in Biophysics at the University of Washington and is currently attending the University of Colorado – Anschutz Medical Campus to obtain his Ph.D. in Immunology. Between his undergraduate and graduate studies, Mr. DeGolier trained for several years with Dr. Courtney Crane at the Seattle Children’s Research Institute, working to characterize the tumor immune microenvironment in pediatric brain tumors, and to develop genetically engineered macrophages as a method to locally deliver immunomodulatory therapeutics within these tumors. Mr. DeGolier is presently training with Dr. Terry Fry, investigating the immunobiology of CAR T cells in the context of pediatric leukemias. His primary interests lie in studying the shortcomings in CAR T cell function that allow relapses to occur, and how T cell-intrinsic phenotypic heterogeneity contributes to functional differences in CAR T cell populations.

            • Leigh Ellis, Ph.D.
              Acting Associate Professor of Medicine, Cedars-Sinai Medical Center
              Biography

                Dr. Leigh Ellis is the scientific director of the Center for Urologic Research Excellence at Cedars-Sinai Cancer and Acting Associate Professor of Medicine in the Division of Medical Oncology, Department of Medicine and Biomedical Sciences at Cedars-Sinai Medical Center. The Ellis lab focuses on dissecting underlying genetic/epigenetic mechanisms of aggressive prostate cancer. Our overall goal is to identify novel genomic/epigenomic mechanisms which will lead to discovery of biomarkers and therapeutic targets for clinical testing, with a specific focus on tumor and immune cell lineage plasticity in prostate cancer driven by the loss of the tumor suppressor protein, retinoblastoma-1 (RB) and collaboration with the histone modifying enzyme enhancer of zeste homolog-2 (EZH2).

              • Gordon J. Freeman, PhD
                Professor of Medicine, Harvard Medical School
                Biography

                  Gordon J. Freeman, PhD is in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School.  Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University.  


                  Dr. Freeman’s research identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction.  He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. This work provided the foundation for developing immune checkpoint blockade immunotherapies.  He is a Fellow of the AACR Academy and received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology, 2017 Warren Alpert Foundation award, 2020 Richard Smalley, MD, memorial award from the Society for Immunotherapy of Cancer, and membership in the National Academy of Inventors for his work that led to development of PD-L1/PD-1 pathway blockade for cancer immunotherapy.

                • Keith Knutson, PhD
                  Consultant and Director, Department of Immunology, Mayo Clinic
                  Biography

                    Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, with a joint appointment in the Department of Cancer Biology.  Dr. Knutson serves as the Director of the Mayo Clinic in Florida Cell and Tissue Analysis Shared Resource.  He is also Co-director of the Mayo Clinic Enterprise Cancer Center’s Cancer Immunology and Immunotherapy Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of Professor of Immunology, Mayo Clinic College of Medicine and Science. Dr. Knutson is recognized with the distinction of the Andrew A. and Mary S. Sugg Professor of Cancer Research. Dr. Knutson received his B.S. in Microbiology at the University of Washington. He earned his Ph.D. in Physiology and Pharmacology from the University of Georgia and completed two postdoctoral fellowships in immunology, one at the University of British Columbia and the other at the University of Washington. Dr. Knutson is internationally recognized in the field of cancer immunology.  His research focuses on the immunology and immunotherapy of prevalent women’s cancer namely breast, ovarian, and lung cancers, both the basic immunobiology and clinical translation, including clinical trials. His contributions to science include clinical development and testing of tumor antigen-specific vaccines in patients with breast and ovarian cancers. He currently has 4 FDA-approved vaccine trials underway and is principal investigator of 3 Department of Defense grants and 1 NIH grant to test vaccines aimed at preventing recurrence of breast and ovarian cancer, including triple negative breast cancer for which there are no targeted therapies. Dr. Knutson is frequently invited to give presentations on his research both domestically and internationally, and he has authored numerous journal articles, abstracts and other written publications, consistently publishing in high-impact scientific journals. Additionally he holds reviewer responsibilities for several prominent publications. In recognition of his work, Dr. Knutson has received many awards and honors, including the Young Investigator Award-Pharmingen, conferred by the American Association for Cancer Research, and the prestigious Howard Temin Award, conferred by the National Institutes of Health, National Cancer Institute. He is also recognized as the 2017 Investigator of the Year at the Mayo Clinic campus in Florida.  Additionally, he was just recently re-elected as a Komen Scholar for the second time for the period of 2019-2022. In addition to his research activities, Dr. Knutson is active in education and has mentored postdoctoral fellows, research associates and medical students, among others. He holds full faculty privileges in Immunology in Mayo Clinic Graduate School of Biomedical Sciences. Dr. Knutson’s has several current and past memberships with professional organizations which include the Breast Cancer Research Program and the Ovarian Cancer Research Program of the United States Department of Defense, the Tumor Microenvironment Study Section of the U.S. National Institutes of Health Center for Scientific Review, and the Education and Training Committee for the Society for the Immunotherapy of Cancer. He is the principal investigator of the Artemis Project, National Breast Cancer Coalition, where he is working to produce prevention vaccines for breast cancer.

                  • Dave Mason, PhD
                    Technical Sales Specialist, Visiopharm
                    Biography

                      Dave Mason is a Technical Specialist in Image Analysis supporting Visiopharm's UK and European Sales team. Trained as a Cell Biologist and Microbiologist he has spent over a decade in Academia specializing in Light Microscopy and Digital Image Analysis.

                    • Brian McWilliams, PhD
                      IP/WB Manager at Fortis Life Sciences
                      Biography

                        Brian McWilliams, Ph.D., received his undergraduate degree in Biochemistry from Oklahoma State University in 2001. His Ph.D. was completed with Dr. Joseph Petrosino at Baylor College of Medicine, where he studied vaccine design and diagnostics for bacterial pathogens Bacillus anthracis and Francisella tularensis.  After a brief post-doc at The University of Texas – Medical Branch in Galveston, TX, he joined Bethyl Laboratories. He is currently the IP/WB Manager at Fortis Life Sciences, serving to maintain the existing catalog of Bethyl antibodies and validate new polyclonal and monoclonal antibody products from the R&D pipeline.

                      • Jun Park, PhD
                        Senior Scientist, MilliporeSigma
                        Biography
                          Jun Park, Ph. D. is Senior Scientist and Applications Lead at MilliporeSigma. He studied Biomaterials and Immunology at University of Toronto and did his postdoctoral work at Harvard Medical School investigating small molecule regulators of beta integrins. Since joining MilliporeSigma in 2006, his primary works have focused on the novel detection technologies, Western blotting, and cell based assays.
                        • Dayana Rivadeneira, PhD
                          Research Assistant Professor, Department of Immunology University of Pittsburgh
                          Biography

                            Dr. Dayana Rivadeneira is a research assistant professor in the Department of Immunology at the University of Pittsburgh. Dr. Rivadeneira received her Ph.D. in Genetics at Thomas Jefferson University where she explored mechanisms of cell cycle dysregulation in cancer. Her preclinical focus on CDK4/6 inhibition as a potential therapeutic target contributed to the launch of multiple clinical trials spanning several cancer types.During her postdoctoral years she examined the role of metabolism and mitochondrial dynamics in the tumor microenvironment and how it shapes anti-tumor immunity. Along these lines, her most recent efforts have centered on developing means by which the tumor microenvironment could be metabolically reprogrammed, with a specific focus on oncolytic viruses, as well as the effects of systemic metabolic disorders in immunotherapy response.

                          • Leah Schmidt, PhD
                            Postdoctoral Fellow, Fred Hutchinson Cancer Research Center
                            Biography

                              Leah Schmidt, PhD, is a postdoctoral fellow in the laboratory of Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center, and an AACR-AstraZeneca Immuno-oncology Research Fellow. Her research is focused on utilizing preclinical models for refining and improving engineered T cell therapies against solid tumors, including lung and pancreatic cancers. Prior to Fred Hutch, Dr. Schmidt completed her PhD thesis in the laboratory of Dr. Tyler Jacks at the Massachusetts Institute of Technology, where she studied the roles of natural killer cells in shaping anti-tumor immune responses in genetically engineered preclinical models. Her overarching scientific interest is uncovering strategies for improving patient outcomes by leveraging the immune system against human disease.

                            • Peter Sullivan, PhD
                              Postdoctoral Fellow, Laboratory of Dr. Rimas Orentas, Seattle Children's Research Institute
                              Biography

                                Dr. Peter Sullivan obtained his B.A. in Biology and Chemistry from Lake Forest College  and his Ph.D. from Cornell University, studying the molecular biology underlaying the neurodegenerative diseases ALS and FTLD. After obtaining his Ph.D., he moved into CD8 T cell biology to better understand how the immune system functions in health and disease with the goal of applying this knowledge to novel cellular therapies. He is currently a post-doctoral fellow working with Dr. Rimas Orentas at Seattle Children's Research Institute. His research is focused on optimizing CAR T cell therapy for the treatment of pediatric solid tumors. Dr. Sullivan is excited to continue working in the emerging field of engineered cellular therapy.

                              • Yousef Zakharia, MD
                                Associate Professor of Medicine, University of Iowa
                                Biography

                                  I am a medical oncologist and hematologist, my clinical expertise is in melanoma and genitourinary malignancy, my clinical and translational research has been geared towards experimental therapeutics in renal cancer and melanoma. I serve as the Director for our Phase 1 Program at the Holden Comprehensive Cancer Center. Being at an NCI-designated Comprehensive Cancer Center offers me the resources to be on the cutting edge of cancer science and provides a unique opportunity to treat my patients on clinical trials at different phases. One of my main research projects has been an investigator initiated clinical trial combining high-dose selenium with axitinib in metastatic clear cell renal cell carcinoma. We presented the preliminary promising results at the American Urology Association 2020 Annual Meeting and we are in the process of putting a manuscript together. I also helped designing and leading a multi-center trial and protocol for a phase 1/2 clinical trial combining indoximod “an IDO inhibitor” with checkpoint inhibitors in metastatic melanoma patients. I had the honor of presenting the preliminary results of this trial at the American Association of Cancer Research (AACR) Annual Meeting Plenary Session in Washington, D.C, April 2017, and at the CRI-CIMT-EATI-AACR annual meeting in Frankfurt, Germany, September 2017, and the final results at the ASCO Annual Meeting, 2018.

                                Sponsored by

                                For information on becoming a sponsor or exhibitor, please click here.


                                C.E. Credits

                                The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                Committee

                                To download the Program Committee brochure here.


                                • Tullia C. Bruno, PhD

                                  Tullia C. Bruno, PhD, is an Assistant Professor in the Department of Immunology at the University of Pittsburgh and a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. She obtained her Ph.D ...

                                  See more See less
                                • Shannon K. Oda, PhD

                                  Dr. Shannon Oda earned a Ph.D. in Immunology from the University of Colorado Anschutz Medical Campus and completed her postdoctoral training with Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center. She has received several awards, including the Evergreen Fund ...

                                  See more See less
                                • Houssein Sater, MD

                                  Dr. Sater is a translational physician scientist (hematologist/oncologist) with special interest in immune therapy of cancer. He leads the Genitourinary Malignancies Branch efforts at understanding the role of cancer immunotherapy on the tumor (immune and non-immune) ...

                                  See more See less
                                Help

                                General Labroots Questions

                                email support@labroots.com  

                                Virtual Events and Webinars

                                Supported Configurations

                                • Operating System Internet Explorer Firefox Chrome Safari
                                  Vista IE8+ FF10+ Chrome15+
                                  Windows 7 IE8+ FF10+ Chrome15+
                                  Windows 8 IE10 FF10+ Chrome15+
                                  Mac OS X   FF10+ Chrome15+ Safari5.1+
                                • Cookie settings: session cookies enabled
                                • Browser configuration must have JavaScript enabled
                                • Adobe Flash player 10.2 or later

                                To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                Internet Connection

                                • A minimum of 100Kbps is recommended for audio-only events
                                • A minimum of 300Kbps is recommended for speaker on-video events

                                Computer Equipment

                                • Screen Resolution: Minimum 1024x768
                                • Video Card: 65,000 colors minimum
                                • Sound card and speakers (or headphones) for hearing webcast in full format
                                • Audio Card: 16-bit minimum
                                • RAM: 512MB of free RAM

                                Firewall Protocol

                                • HTTP on port 80 or HTTPS on port 443
                                • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                Work-At-Home Attendees

                                • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                For A Seamless Experience

                                When using a mobile device, FREE Mobile Apps are available:

                                - For viewing Webinars:

                                - For viewing Virtual Events

                                Attendee Guide

                                • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                Virtual Event and Webinar Support:

                                Continuing Education (CME/CE) Support

                                Demographics

                                Specialty

                                Cancer

                                Research And Development

                                Research

                                Cancer Research

                                Immunology

                                Molecular Biology

                                Disease

                                Molecular Genetics

                                Cell

                                Gene

                                Health

                                Cell Biology

                                Drug Development

                                Biotechnology

                                Genetics

                                Geography

                                Asia36%

                                North America27%

                                Europe23%

                                Africa7%

                                South America5%

                                Oceania1%

                                Registration Source

                                Labroots Registration (Also interested in)55%

                                Website Visitors24%

                                Email Promotions14%

                                Website Banners3%

                                WAVE Newsletter Promotion2%

                                Social Media Promotions1%

                                Job Title

                                Student31%

                                Research Scientist11%

                                Educator/Faculty10%

                                Executive7%

                                Scientist7%

                                Medical Laboratory Technician6%

                                Facility/Department Manager6%

                                Medical Doctor/Specialist5%

                                Biologist3%

                                Clinical Laboratory Scientist3%

                                Lab Management2%

                                Post Doc2%

                                Chemist2%

                                Marketing/Sales1%

                                QC/QA1%

                                Engineer1%

                                Pathologist1%

                                Organization

                                Academic Institution35%

                                Hospital8%

                                Clinical Laboratory7%

                                Biotech Company7%

                                Research Institute5%

                                Government5%

                                Medical School5%

                                Life Science Company3%

                                Pharmaceutical Company3%

                                Government/public3%

                                Distribution/sales2%

                                Medical Center2%

                                Manufacturer - Other1%

                                General Laboratory1%

                                Other4%

                                Posters

                                CALL FOR POSTERS
                                The deadline for electronic submission of your poster title, abstract and poster PDF is May 28th at 5:00pm PDT.

                                POSTER SUBMISSION GUIDELINES
                                Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.

                                SUBMIT YOUR ABSTRACT
                                If you are interested in sponsoring a Poster for this virtual event and generate leads, the cost is $250 and you can submit the poster at advertise@labroots.com.

                                All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by Labroots may display posters at this event.

                                If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. Labroots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

                                Questions? Email Posters@Labroots.com

                                Labroots Policy

                                Additional Authors
                                Add another author
                                Poster Title: 80 characters max
                                Abstract: 500 characters max

                                BACK
                                CONTINUE

                                Choose Additional Events for Submission

                                BACK
                                Loading Comments...
                                Show Resources
                                Event Countdown
                                • 0 Days
                                • 0 Hours
                                • 0 Minutes
                                • 0 Seconds
                                Attendees
                                • See more